Quince Therapeutics Reports 129% Increase in Operating Expenses and $13.4 Million Net Loss for Q3 2025

Quince Therapeutics, Inc. reported a significant increase in operating expenses and net losses for the third quarter of 2025, as detailed in its latest 10-Q filing. The company recorded total operating expenses of $13.4 million for the three months ended September 30, 2025, a 129% increase from $5.9 million in the same period last year. This rise was primarily driven by a 64% increase in research and development expenses, which reached $8.1 million, largely due to ongoing costs associated with the Phase 3 NEAT clinical trial for its lead product, eDSP. The net loss for the quarter was $13.4 million, compared to a loss of $5.5 million in the prior year, reflecting a 145% increase.

In terms of financial position, Quince reported an accumulated deficit of $421 million as of September 30, 2025. The company had cash, cash equivalents, and short-term investments totaling $26.3 million, which it expects will fund operations into the second quarter of 2026. However, management expressed concerns about the sufficiency of these funds to support ongoing operations and indicated the need for additional financing. The company has relied on proceeds from equity offerings, including a recent private placement that raised approximately $11.5 million, and an ATM program that generated $4.3 million in the nine months ended September 30, 2025.

Strategically, Quince has focused on advancing its proprietary AIDE technology platform, which encapsulates drugs in patients' own red blood cells. The company is currently conducting a Phase 3 clinical trial for eDSP, aimed at treating Ataxia-Telangiectasia (A-T), a rare pediatric neurodegenerative disease. As of July 2025, the trial had completed enrollment with 105 participants, and topline results are expected in the first quarter of 2026. The company has also initiated plans to expand its pipeline to include Duchenne muscular dystrophy (DMD) as a second indication for eDSP.

Operationally, Quince's research and development expenses have surged due to increased clinical trial costs, which rose by $7.2 million compared to the previous year. The company has also seen a rise in personnel-related costs, reflecting its investment in talent to support its development efforts. As of September 30, 2025, Quince had 54.5 million shares outstanding, up from 44 million a year earlier, indicating a strategic move to bolster its capital base through equity financing.

Looking ahead, Quince Therapeutics is actively seeking additional funding through various avenues, including public offerings and strategic partnerships, to support its ongoing clinical trials and operational needs. The company remains focused on achieving regulatory approval for eDSP and expanding its product pipeline, although it acknowledges the inherent risks and uncertainties associated with drug development and market conditions.